OBJECTIVE: To evaluate whether exogenous surfactant therapy may be useful in adult patients with acute lung injury or acute respiratory distress syndrome, using a meta-analysis of published clinical trials. DESIGN: A comprehensive literature search was performed to identify all randomized clinical trials examining the effects of the treatment of acute lung injury/acute respiratory distress syndrome with exogenous surfactant in adults. The primary outcome measurement was mortality 28 or 30 days after randomization. Secondary outcome measurements included a change in the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen in the first 24 hours or after 120 hours, the number of ventilation-free days, and any adverse effects. The meta-analysis was performed using the Review Manager 5.0.0 system. PARTICIPANTS: Randomized clinical trials. INTERVENTION: Meta-analysis of 9 trials. MEASUREMENTS AND MAIN RESULTS: Nine trials involving 2,575 patients were included in the meta-analysis. The analysis showed that treatment with exogenous pulmonary surfactant does not decrease mortality significantly. There was a significant effect of exogenous surfactant treatment on the change in the partial pressure of arterial oxygen/fraction of inspired oxygen ratio in the first 24 hours but this was lost by 120 hours. The duration of ventilation trended lower in surfactant-treated patients but this was not significant. In addition, surfactant-treated patients had a significantly higher risk of adverse effects. CONCLUSIONS: An exogenous surfactant may improve oxygenation over the first 24 hours after administration. However, treatment does not improve mortality and oxygenation over ≥120 hours after administration and results in a high rate of adverse effects. Therefore, the present data suggest that an exogenous surfactant cannot be considered an effective adjunctive therapy in patients with acute lung injury/acute respiratory distress syndrome.
OBJECTIVE: To evaluate whether exogenous surfactant therapy may be useful in adult patients with acute lung injury or acute respiratory distress syndrome, using a meta-analysis of published clinical trials. DESIGN: A comprehensive literature search was performed to identify all randomized clinical trials examining the effects of the treatment of acute lung injury/acute respiratory distress syndrome with exogenous surfactant in adults. The primary outcome measurement was mortality 28 or 30 days after randomization. Secondary outcome measurements included a change in the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen in the first 24 hours or after 120 hours, the number of ventilation-free days, and any adverse effects. The meta-analysis was performed using the Review Manager 5.0.0 system. PARTICIPANTS: Randomized clinical trials. INTERVENTION: Meta-analysis of 9 trials. MEASUREMENTS AND MAIN RESULTS: Nine trials involving 2,575 patients were included in the meta-analysis. The analysis showed that treatment with exogenous pulmonary surfactant does not decrease mortality significantly. There was a significant effect of exogenous surfactant treatment on the change in the partial pressure of arterial oxygen/fraction of inspired oxygen ratio in the first 24 hours but this was lost by 120 hours. The duration of ventilation trended lower in surfactant-treated patients but this was not significant. In addition, surfactant-treated patients had a significantly higher risk of adverse effects. CONCLUSIONS: An exogenous surfactant may improve oxygenation over the first 24 hours after administration. However, treatment does not improve mortality and oxygenation over ≥120 hours after administration and results in a high rate of adverse effects. Therefore, the present data suggest that an exogenous surfactant cannot be considered an effective adjunctive therapy in patients with acute lung injury/acute respiratory distress syndrome.
Authors: Soo-Ho Choi; Aaron M Wallace; Dina A Schneider; Elianne Burg; Jungsu Kim; Elena Alekseeva; Niki Dj Ubags; Carlyne D Cool; Longhou Fang; Benjamin T Suratt; Yury I Miller Journal: JCI Insight Date: 2018-08-23
Authors: Ahilanandan Dushianthan; Victoria Goss; Rebecca Cusack; Michael P W Grocott; Anthony D Postle Journal: BMC Pulm Med Date: 2014-02-01 Impact factor: 3.317
Authors: J Zebialowicz Ahlström; F Massaro; P Mikolka; R Feinstein; G Perchiazzi; O Basabe-Burgos; T Curstedt; A Larsson; J Johansson; A Rising Journal: Respir Res Date: 2019-11-06
Authors: Francesco Cattel; Susanna Giordano; Cecilia Bertiond; Tommaso Lupia; Silvia Corcione; Matilde Scaldaferri; Lorenzo Angelone; Francesco Giuseppe De Rosa Journal: Respir Physiol Neurobiol Date: 2021-02-28 Impact factor: 2.821
Authors: Ahilanandan Dushianthan; Rebecca Cusack; Victoria Goss; Anthony D Postle; Mike P W Grocott Journal: Crit Care Date: 2012-11-22 Impact factor: 9.097
Authors: Ann M Czyzewski; Lynda M McCaig; Michelle T Dohm; Lauren A Broering; Li-Juan Yao; Nathan J Brown; Maruti K Didwania; Jennifer S Lin; Jim F Lewis; Ruud Veldhuizen; Annelise E Barron Journal: Sci Rep Date: 2018-05-01 Impact factor: 4.379